TrialThe Lancet. Haematology2021

Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: a multicentre, single-arm, phase 2 trial.

Jacob D Soumerai et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.